• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival

    2017-02-10 08:08:22

    Shanghai, China

    The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival

    Xin-Zhe Yu, Zhong-Yi Guo, Yang Di, Feng Yang, Qi Ouyang, De-Liang Fu and Chen Jin

    Shanghai, China

    BACKGROUND: Previous researches in pancreatic cancer demonstrated a negative correlation between secreted protein acidic and rich in cysteine (SPARC) expression in primary tumor and survival, but not for SPARC expression in lymph node. In the present study, we aimed to evaluate the SPARC expression in various types of tissues and its impact on patients' prognosis.

    METHODS: The expression of SPARC was examined by immunohistochemistry in resected pancreatic cancer specimens. Kaplan-Meier analyses and Cox proportional hazards regression were applied to assess the mortality risk.

    RESULTS: A total of 222 tissue samples from 73 patients were collected to evaluate the SPARC expression, which included 73 paired primary tumor and adjacent normal tissues, 38 paired metastatic and normal lymph nodes. The proportion of positive SPARC expression in metastatic lymph node was high (32/38), whereas in normal lymph node it was negative (0/38). Positive SPARC expression in primary tumor cells was associated with a signifcantly decreased overall survival (P=0.007) and disease-free survival (P=0.003), whereas in other types oftissues it did not show a predictive role for prognosis. Univariate and multivariate analyses both confrmed this signifcance.

    CONCLUSION: SPARC can serve a dual function role as both predictor for prognosis and potentially biomarker for lymph node metastasis in resected pancreatic cancer patients.

    (Hepatobiliary Pancreat Dis Int 2017;16:104-109)

    pancreatic cancer;

    SPARC expression;

    immunohistochemistry;

    prognostic marker;

    lymph node metastasis

    Introduction

    Pancreatic cancer is the fourth most common cause of cancer death in the Western world.[1]Despite the impressive progress in basic and clinical research, treating pancreatic cancer is still a therapeutic challenge with dismal 5-year survival rates less than 5%.[2,3]In fact, the diffcult surgical approach, resistance to conventional therapies, and the subsequent low survival rate can all contribute to the high-frequency occurrence of lymph node metastasis.[4-6]Thus, fnding an effective biomarker for the lymph node metastasis is critically important.[7]

    Secreted protein acidic and rich in cysteine (SPARC), also known as the osteonectin and basement membrane-40 (BM-40) protein, is a member of the matricellular family of proteins.[8,9]SPARC was frst identifed in bone and later in platelets as well as tumor tissues,[2]which plays a pivotal role in cell proliferation,[10]angiogenesis[11]and cell migration.[12]SPARC has been reported to be either up-regulated or down-regulated depending on cancer types,[13]suggesting its complex role in the tumorigenesis. In addition, a hypothesis is proposed that SPARC may act as an albumin “sticker”, which facilitates the deliveryof nab-paclitaxel towards pancreatic cancer cells.[14-16]Recently, SPARC overexpression has been described in colorectal cancer,[17]gastric cancer[18]and pancreatic cancer,[19]and has been associated with poor prognosis.[20-22]Normally, increased SPARC expression has often been found in the stromal area rather than tumor cells, especially in pancreatic cancer.[23]However, no data are available in regards to the SPARC expression in metastatic lymph node and its correlation with survival beneft.

    To the best of our knowledge, this study frstly reported data on SPARC expression in lymph node (normal and metastatic) as well as primary tumor of pancreatic cancer patients, and its correlation with the survival beneft. We aimed to explore the dual function role of SPARC as both prognostic predictor and biomarker for the lymph node metastasis in pancreatic cancer patients.

    Methods

    Clinicopathological data and tissue selection

    We retrospectively reviewed 73 patients who underwent radical pancreatic cancer surgery from January 2007 to December 2013 in our hospital. All patients were confrmed to have pancreatic ductal adenocarcinoma by pathologists. Among the 73 patients, 50 were pancreatic head carcinoma, and 23 were pancreatic body or tail carcinoma. A total of 222 tissue samples from these patients were eligible to evaluate the SPARC expression, which included 73 paired primary tumor and matched adjacent normal tissues, 38 paired metastatic and matched normal lymph nodes. All of the clinical and pathologic information was acquired from a regular updated clinical database. The methods for follow-up included, but were not limited to, centers for disease control, outpatient, telephone, and mail. The study was approved by the review board committee of Fudan University.

    SPARC immunohistochemistry

    Formalin-fxed, paraffn-embedded blocks of tissues from each patient were analyzed with immunohistochemistry, which was performed according to the standard protocol of previous report.[24]Briefy, resected tissues were sliced into 4-5 μm thickness, de-paraffnized, and bathed in citrate buffer at 95 ℃ for 40 minutes for antigen retrieval. The slices were then incubated at 4 ℃for 13 hours with a monoclonal SPARC antibody (Abcam plc, Cambridge, UK), and stained with an avidin-biotin system (Shanghai High-tech Inc., Shanghai, China). All of the nuclei were counterstained with hematoxylin.

    SPARC staining analyses were evaluated by two observers (Di Y and Yang F) blinded to the clinical data and treatment arm. Any discrepancy was resolved by a third observer (Ouyang Q). The slices were evaluated for the distribution of staining in the tissues (cytoplasm or stroma). Five microscopic felds from each sample were randomly chosen. The positive cell number and total cell number in every feld were counted. The percentage of positive cell=positive cells/total cells. SPARC immunolabeling was categorized as negative when the intensity was absent to weak (+) and if the extent was less than 10%; immunolabeling was positive if the intensity was moderate (++) to strong (+++), and the extent was ≥10%. SPARC was categorized as positive or negative for the primary tumor site, adjacent normal tissue and lymph node: Tumor-/-Stroma, Tumor+/-Stroma, Tumor-/+Stroma, Tumor+/+Stroma.

    Statistical analysis

    Overall survival (OS) was defned as the time period from surgery to death by any cause. Disease-free survival (DFS) was defned as the time from surgery to the development of either local recurrence or distant metastasis. The Pearson's Chi-square test or Fisher's exact probability test was used to compare clinicopathological characteristics of patients with positive and negative SPARC expression. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the mortality risk associated with the presence or absence of tumor SPARC and stromal SPARC status. All of the statistical analyses were performed with SPSS software (version 22.0; IBM Inc., NY, USA). APvalue of <0.05 was considered statistically signifcant.

    Results

    Patient characteristics

    A total of 73 pancreatic cancer patients were analyzed in the pool, with a median follow-up time of 30 months (the cut-off date for follow-up was December, 30th 2014). We collected 73 primary tumor site tissues, 73 adjacent normal tissues, 38 metastatic lymph nodes and 38 matched normal lymph nodes.

    SPARC expression in tissues

    The SPARC expression was observed both in the cytoplasm of tumor cells and cytoplasm of fbroblasts in the stromal area (Fig. 1). From the results of the immunohistochemistry we found that the SPARC expression was strongly overexpressed in cancer cells and stromal fbroblasts immediately adjacent to cancer cells, suggesting its role in the tumor-stroma interaction. However, SPARC expression was weak or absent in normal pancre-atic ductal cells. Among the 73 tissues from the primary tumor site: twenty-one samples (28.8%) were classifed as Tumor-/+Stroma, and the other 52 samples (71.2%) were classifed as Tumor+/+Stroma; among the 73 tissues from the adjacent normal tissues: ffteen samples (20.5%) were classifed as Stroma+, the other 58 samples (79.5%) were classifed as Stroma-; whereas in 38 tissues from the metastatic lymph node: eight samples (21%) were classifed as Tumor-/+Stroma, six samples (15.8%) were classifed as Tumor-/-Stroma, the other 24 samples (63.2%) were classifed as Tumor+/+Stroma; however, in all tissues from the normal lymph node, there were none SPARC expression. Refer to previous reports,[25-27]we examined SPARC expression in the primary tumor site and its association with major clinicopathological parameters. As shown in Table 1, baseline data and risk factors such as age, gender, tumor size, nodal status, resection margin were comparable between the Tumor-/+Stroma and Tumor+/+Stroma groups.

    Fig. 1. Patterns of immunohistochemical expression of SPARC in resected pancreatic ductal adenocarcinoma specimens (original magnification ×100). A: Negative staining (-); B: Weakly staining (+); C: Moderately staining (++); D: Strongly staining (+++). ○: positive expression of SPARC.

    SPARC expression and patients prognosis

    We performed survival analyses in dependence of SPARC expression within all tissue groups. Fig. 2 indicated that negative SPARC expression in tumor cell was associated with a signifcantly increased OS (HR=0.44; 95% CI: 0.24-0.82;P=0.007) and DFS (HR=0.38; 95%CI: 0.20-0.71;P=0.003). However, there seemed no connection between SPARC expression and survival benefts in the metastatic lymph node group (Fig. 3). It was also the same situation in adjacent normal tissue group.

    Table 1. Clinicopathological characteristics in relation to SPARC expression in the primary tumor (n, %)

    Fig. 2. Kaplan-Meier overall survival curves (A) and disease-free survival curves (B) for the SPARC expression negative vs positive in the primary tumor site.

    Fig. 3. Kaplan-Meier overall survival curves (A) and disease-free survival curves (B) for the SPARC expression negative vs positive in the metastatic lymph nodes.

    Table 2. Univariate and multivariate analyses of overall survival after surgery

    Univariate and multivariate analyses of OS

    Univariate analysis revealed that the following parameters were associated with increased mortality: positive SPARC expression in the primary tumor (HR=2.28; 95% CI: 1.22-4.25;P=0.007); metastatic lymph node (HR=2.09; 95% CI: 1.22-3.58;P=0.005); advanced tumor grade (HR=2.23; 95% CI: 1.23-4.04;P=0.008); positive resection margin (HR=1.80; 95% CI: 1.05-3.08;P=0.026); without adjuvant chemotherapy (HR=2.96; 95% CI: 1.56-5.61;P=0.001). In a further step of multivariate analysis, only SPARC expression in the primary tumor (HR=2.37; 95% CI: 1.20-4.67;P=0.013) and without adjuvant chemotherapy (HR=3.41; 95% CI: 1.62-7.18;P=0.001) retained their negative impact on survival (Table 2).

    Discussion

    SPARC positive or overexpression has often been related to bad prognosis in various malignant tumors,[28-31]several studiesin vivoandin vitroalso confrmed this.[32,33]However, the exact mechanism of action remains unclear.[34,35]

    This study shows that positive SPARC expression in the primary tumor cell is associated with a signifcantly decreased OS and DFS, which is generally in accordance with Infante et al's report.[25]In their study, pancreatic cancer patients with positive SPARC expression in primary tumor had a signifcant worse prognosis than those with negative SPARC expression (P<0.001). Notably, this difference was restricted to SPARC expression in the stromal area, they did not fnd a correlation between tumor cell SPARC expression and survival (P=0.13). In another report by Sinn et al,[36]both positive stromal and cytoplasmic SPARC expression was associated with worse DFS and OS. In our study, however, SPARC staining within stromal area was observed in all samples from the primary tumor site; patients with Tumor-/+Stroma had a signifcant longer median survival compared with those with Tumor+/+Stroma. For other type of tissues, including adjacent normal tissues, metastatic lymph nodes, and normal lymph nodes, we did not fnd a correlation between SPARC expression and survival.

    Univariate analysis indicated that positive SPARCexpression in the primary tumor, metastatic lymph node, advanced tumor grade, positive resection margin, without adjuvant chemotherapy were all risk factors of overall survival. Multivariate regression analysis showed that positive SPARC expression in the primary tumor was still an independent prognostic factor (HR=2.37; 95% CI: 1.20-4.67;P=0.013) after adjustment for metastatic lymph node, advanced tumor grade, without adjuvant chemotherapy and positive resection margin.

    A highlight of this study is that SPARC can potentially serve as a biomarker for the lymph node metastasis. SPARC expression in the metastatic lymph node is higher than that in the matched normal lymph node. Comparing with CA19-9, a generally accepted biomarker for early diagnosis and effcacy evaluation, with a sensitivity of 78.6% and specifcity of 87.3%,[37]SPARC in our study yield a sensitivity of 84.2% (32/38) and specifcity of 100% (38/38). Nevertheless, this result should be treated with caution due to our limited sample size and a retrospective feature. Further validation is needed in a larger cohort study.

    For resectable pancreatic cancer patients, chemotherapy always plays a pivotal role. Whether chemotherapy will have an impact on the relationship between SPARC and survival remains controversial. Sinn and coworkers[36]found that the negative impact of SPARC on survival was only restricted to patients who were treated with gemcitabine. Infante et al[25]demonstrated that chemotherapy did not affect the correlation between SPARC and survival.

    Our study has several limitations. First one is a retrospective feature with a relatively small size. However, all of the patients and samples were recruited on a consecutive time basis to maximally avoid selection bias. Second, only 38 metastatic lymph nodes were acquired for analysis which may cause type II error. Third, we only used immunohistochemical staining which is not sensitive for protein detection, other methods such as Western blotting and ELISA may improve the sensitivity. Another limitation is that, according to Von Hoff et al,[14]in patients with pancreatic cancer who treated with nab-paclitaxel, SPARC improves chemotherapy response. None of our patient received nab-paclitaxel treatment because nab-paclitaxel is recommended for advanced pancreatic cancer rather than resectable cancer; nab-paclitaxel is expensive and there is no insurance coverage in China now.

    In summary, positive SPARC expression predicts poor prognosis, additionally, SPARC has the potential to serve as a biomarker for lymph node metastasis in resected pancreatic cancer patients. Future randomized controlled trials are needed to validate our results.

    Contributors:YXZ and DY proposed the study. YXZ, GZY and DY carried out the research. YXZ drafted the manuscript. DY, YF and OQ collected and analyzed the data. FDL and JC kindly offered valuable suggestions about the experiment design. YXZ and GZY contributed equally to this article. JC is the guarantor.

    Funding:This study was supported by grants from the National Natural Science Foundation of China (81201896 and 81071884) and the Research Fund for the Doctoral Program of Higher Education of China (20130071110052).

    Ethical approval:All specimens were collected in accordance with informed consents of patients, and all procedures complied with the protocol approved by the review board committee of Fudan University.

    Competing interest:No benefts in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.

    2 Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013;32:585-602.

    3 Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617.

    4 Yang F, Jin C, Yang D, Jiang Y, Li J, Di Y, et al. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur J Cancer 2011;47:1873-1882.

    5 Yang F, Jin C, Subedi S, Lee CL, Wang Q, Jiang Y, et al. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev 2012;38:566-579.

    6 Wagner M, Dikopoulos N, Kulli C, Friess H, Büchler MW. Standard surgical treatment in pancreatic cancer. Ann Oncol 1999;10:247-251.

    7 Kim KY, Lee GY, Cha IH. Biomarker detection for the diagnosis of lymph node metastasis from oral squamous cell carcinoma. Oral Oncol 2012;48:311-319.

    8 Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995;43:791-800.

    9 Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 1999;31:1363-1366.

    10 Ryall CL, Viloria K, Lhaf F, Walker AJ, King A, Jones P, et al. Novel role for matricellular proteins in the regulation of islet β cell survival: the effect of SPARC on survival, proliferation, and signaling. J Biol Chem 2014;289:30614-30624.

    11 Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 2006;118:310-316.

    12 Kunigal S, Gondi CS, Gujrati M, Lakka SS, Dinh DH, Olivero WC, et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 2006;29:1349-1357.

    13 Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:691-705.

    14 Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, SmithLS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-4554.

    15 Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014;63:974-983.

    16 Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64.

    17 Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/ SPARC genes. Int J Cancer 1995;64:70-75.

    18 Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinicpathologic signifcance. Br J Cancer 2004;91:1924-1930.

    19 Kalea?as?o?lu F, Berger MR. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer. World J Gastroenterol 2014;20:14747-14759.

    20 Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical signifcance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003;97:2412-2419.

    21 Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001;166:2495-2499.

    22 Franke K, Carl-McGrath S, R?hl FW, Lendeckel U, Ebert MP, T?nzer M, et al. Differential expression of SPARC in intestinaltype gastric cancer correlates with tumor progression and nodal spread. Transl Oncol 2009;2:310-320.

    23 Edmonds C, Cengel KA. Tumor-Stroma interactions in pancreatic cancer: Will this SPARC prove a raging fre? Cancer Biol Ther 2008;7:1816-1817.

    24 Nakashima S, Kobayashi S, Sakai D, Tomokuni A, Tomimaru Y, Hama N, et al. Prognostic impact of tumoral and/or peritumoral stromal SPARC expressions after surgery in patients with biliary tract cancer. J Surg Oncol 2014;110:1016-1022.

    25 Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fbroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-325.

    26 Mantoni TS, Schendel RR, R?del F, Niedobitek G, Al-Assar O, Masamune A, et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 2008;7:1806-1815.

    27 Miyoshi K, Sato N, Ohuchida K, Mizumoto K, Tanaka M. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res 2010;30:867-871.

    28 Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, et al. Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis 2012;15:150-156.

    29 Huang Y, Zhang J, Zhao YY, Jiang W, Xue C, Xu F, et al. SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer 2012;31:541-548.

    30 Wang L, Yang M, Shan L, Qi L, Chai C, Zhou Q, et al. The role of SPARC protein expression in the progress of gastric cancer. Pathol Oncol Res 2012;18:697-702.

    31 Jiang J, Song Y, Liu N, Lin C, Zhao S, Sun Y, et al. SPARC and Vav3 expression in meningioma: factors related to prognosis. Can J Neurol Sci 2013;40:814-818.

    32 Funel N, Costa F, Pettinari L, Taddeo A, Sala A, Chiriva-Internati M, et al. Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 2010;10:545-552.

    33 Liu H, Zhang H, Jiang X, Ma Y, Xu Y, Feng S, et al. Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells. Cancer Biother Radiopharm 2011;26:705-715.

    34 Seux M, Peuget S, Montero MP, Siret C, Rigot V, Clerc P, et al. TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene 2011;30:3049-3061.

    35 Chetty C, Dontula R, Ganji PN, Gujrati M, Lakka SS. SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells. Biochem Biophys Res Commun 2012;417:874-879.

    36 Sinn M, Sinn BV, Striefer JK, Lindner JL, Stieler JM, Lohneis P, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 2014;25:1025-1032.

    37 Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, et al. Comparison of the sensitivity and specifcity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-349.

    Received February 24, 2016

    Accepted after revision September 16, 2016

    Author Affliations: Department of Pancreatic Surgery (Yu XZ, Guo ZY and Jin C) and Department of Pathology (Ouyang Q), Huashan Hospital; Institute of Pancreatic Disease (Di Y, Yang F and Fu DL); Fudan University, Shanghai 200040, China

    Chen Jin, MD, PhD, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, 12# Middle Urumqi Road, Shanghai 200040, China (Email: galleyking@hotmail.com)

    The abstract of this article was presented as a poster at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015 and at the Joint Meeting of Pancreatic Cancer Committee of Chinese Anti-Cancer Association & International Association of Pancreatology 2015 (PCCA&IAP 2015).

    ? 2017, Hepatobiliary Pancreat Dis Int. All rights reserved.

    10.1016/S1499-3872(16)60168-6

    Published online January 16, 2017.

    日韩欧美一区二区三区在线观看| 国产精品免费一区二区三区在线| 90打野战视频偷拍视频| 丁香欧美五月| 女人高潮潮喷娇喘18禁视频| 亚洲va日本ⅴa欧美va伊人久久| 精品人妻在线不人妻| 国产高清视频在线播放一区| 在线观看www视频免费| 国产1区2区3区精品| 91九色精品人成在线观看| 一区二区三区国产精品乱码| 精品久久久精品久久久| 国产日韩一区二区三区精品不卡| 伦理电影免费视频| 婷婷丁香在线五月| 一夜夜www| 最近最新免费中文字幕在线| 日本a在线网址| 日日干狠狠操夜夜爽| 免费人成视频x8x8入口观看| 国产成人精品久久二区二区91| 男人的好看免费观看在线视频 | 免费在线观看视频国产中文字幕亚洲| 久久伊人香网站| 午夜福利成人在线免费观看| 欧美另类亚洲清纯唯美| 中出人妻视频一区二区| 两人在一起打扑克的视频| 老司机午夜十八禁免费视频| 国产成人欧美在线观看| 国产亚洲欧美98| 97超级碰碰碰精品色视频在线观看| 免费不卡黄色视频| 国产激情久久老熟女| 一本综合久久免费| 乱人伦中国视频| 变态另类丝袜制服| 如日韩欧美国产精品一区二区三区| 国产av一区在线观看免费| 色婷婷久久久亚洲欧美| 午夜免费成人在线视频| 淫秽高清视频在线观看| 精品熟女少妇八av免费久了| 波多野结衣巨乳人妻| 悠悠久久av| 亚洲久久久国产精品| a在线观看视频网站| 欧洲精品卡2卡3卡4卡5卡区| 女性被躁到高潮视频| 日本五十路高清| 国产成人精品在线电影| 免费在线观看黄色视频的| 国产日韩一区二区三区精品不卡| 国产99白浆流出| 日本欧美视频一区| 成人国产一区最新在线观看| 国产男靠女视频免费网站| 中文字幕人成人乱码亚洲影| 免费少妇av软件| 亚洲国产毛片av蜜桃av| 国产蜜桃级精品一区二区三区| 美女高潮喷水抽搐中文字幕| 国产黄a三级三级三级人| 美女高潮到喷水免费观看| 黄频高清免费视频| 亚洲国产欧美一区二区综合| 男人的好看免费观看在线视频 | 国产精品久久久久久精品电影 | 成人18禁在线播放| 在线观看66精品国产| 男女做爰动态图高潮gif福利片 | 国产精品98久久久久久宅男小说| 中文字幕人妻丝袜一区二区| 国产国语露脸激情在线看| 免费一级毛片在线播放高清视频 | 亚洲欧美精品综合久久99| 不卡av一区二区三区| 丁香欧美五月| 午夜免费激情av| 国产日韩一区二区三区精品不卡| 成人av一区二区三区在线看| 亚洲精品国产精品久久久不卡| 在线观看免费午夜福利视频| 热re99久久国产66热| 亚洲少妇的诱惑av| 中文字幕另类日韩欧美亚洲嫩草| 亚洲av电影不卡..在线观看| 久久香蕉精品热| 免费在线观看完整版高清| 大香蕉久久成人网| 精品一区二区三区av网在线观看| 亚洲少妇的诱惑av| а√天堂www在线а√下载| 亚洲欧美精品综合久久99| 精品福利观看| 婷婷六月久久综合丁香| 18美女黄网站色大片免费观看| 欧美大码av| 激情视频va一区二区三区| 十八禁网站免费在线| 午夜精品久久久久久毛片777| 日日爽夜夜爽网站| 亚洲av成人不卡在线观看播放网| av视频在线观看入口| 熟女少妇亚洲综合色aaa.| 一级黄色大片毛片| 88av欧美| 99久久国产精品久久久| 国产亚洲精品av在线| 天天躁狠狠躁夜夜躁狠狠躁| 一边摸一边抽搐一进一小说| 国产三级黄色录像| 波多野结衣一区麻豆| 成人欧美大片| 美女午夜性视频免费| 最近最新中文字幕大全免费视频| 国产欧美日韩一区二区精品| 一区二区日韩欧美中文字幕| 中文字幕人妻丝袜一区二区| 免费看美女性在线毛片视频| 久久久久久久久久久久大奶| 如日韩欧美国产精品一区二区三区| 亚洲国产精品久久男人天堂| 一级毛片女人18水好多| 侵犯人妻中文字幕一二三四区| 国产亚洲精品久久久久久毛片| 波多野结衣高清无吗| 久久亚洲精品不卡| 久久中文字幕人妻熟女| 最近最新免费中文字幕在线| 亚洲欧美激情综合另类| 国产成人av激情在线播放| 一级a爱视频在线免费观看| 黄片小视频在线播放| 亚洲人成电影免费在线| 无限看片的www在线观看| 中文字幕人成人乱码亚洲影| 在线观看免费午夜福利视频| 国产亚洲精品综合一区在线观看 | 又黄又粗又硬又大视频| 9热在线视频观看99| 午夜精品国产一区二区电影| 色在线成人网| 国产成年人精品一区二区| 久久人妻福利社区极品人妻图片| 波多野结衣一区麻豆| 亚洲国产精品久久男人天堂| 欧美最黄视频在线播放免费| 在线十欧美十亚洲十日本专区| 亚洲精品在线美女| 午夜a级毛片| 露出奶头的视频| 亚洲成av人片免费观看| 久久久久久久久免费视频了| 精品人妻1区二区| 18禁美女被吸乳视频| 日本在线视频免费播放| 一边摸一边做爽爽视频免费| 亚洲人成77777在线视频| 亚洲欧美精品综合久久99| 亚洲中文字幕日韩| 淫秽高清视频在线观看| 国产激情久久老熟女| 老汉色∧v一级毛片| 日韩视频一区二区在线观看| 欧洲精品卡2卡3卡4卡5卡区| 午夜视频精品福利| 国产一区二区三区在线臀色熟女| 九色国产91popny在线| 欧美一区二区精品小视频在线| 亚洲九九香蕉| 精品第一国产精品| 久久欧美精品欧美久久欧美| 亚洲国产欧美一区二区综合| 99国产精品99久久久久| 搡老岳熟女国产| 久久性视频一级片| 成人精品一区二区免费| 在线观看免费视频网站a站| 久久久国产成人免费| 欧美绝顶高潮抽搐喷水| 久久精品国产清高在天天线| 亚洲一区高清亚洲精品| 亚洲三区欧美一区| 亚洲中文av在线| 老司机福利观看| 成人特级黄色片久久久久久久| 亚洲狠狠婷婷综合久久图片| 午夜成年电影在线免费观看| 国产野战对白在线观看| a在线观看视频网站| 久久精品国产综合久久久| 久久精品aⅴ一区二区三区四区| 给我免费播放毛片高清在线观看| 手机成人av网站| АⅤ资源中文在线天堂| 成人三级做爰电影| 亚洲精品在线美女| 国产伦人伦偷精品视频| 久久久久久久久免费视频了| 国产一区在线观看成人免费| aaaaa片日本免费| 女同久久另类99精品国产91| 女性生殖器流出的白浆| 日本在线视频免费播放| 亚洲av成人不卡在线观看播放网| 两性夫妻黄色片| 亚洲国产日韩欧美精品在线观看 | 久久精品成人免费网站| 亚洲中文日韩欧美视频| 久久亚洲精品不卡| 精品国产一区二区久久| 欧美不卡视频在线免费观看 | 亚洲第一青青草原| 性少妇av在线| 麻豆久久精品国产亚洲av| 日韩欧美免费精品| 怎么达到女性高潮| 一a级毛片在线观看| 欧美日韩一级在线毛片| 又黄又爽又免费观看的视频| 国产一区二区三区在线臀色熟女| 最新美女视频免费是黄的| 日本五十路高清| 嫁个100分男人电影在线观看| 在线国产一区二区在线| 欧美黑人精品巨大| 免费在线观看黄色视频的| 97人妻天天添夜夜摸| 亚洲无线在线观看| www.熟女人妻精品国产| 乱人伦中国视频| 大香蕉久久成人网| 在线十欧美十亚洲十日本专区| 在线天堂中文资源库| 成人国语在线视频| 亚洲精品在线美女| 国产成人精品无人区| 人妻丰满熟妇av一区二区三区| 国产不卡一卡二| 久99久视频精品免费| 亚洲色图av天堂| or卡值多少钱| 精品国产乱子伦一区二区三区| 国产一区在线观看成人免费| 欧美丝袜亚洲另类 | 国产精品永久免费网站| 久久国产乱子伦精品免费另类| 天堂动漫精品| a级毛片在线看网站| 国产亚洲欧美98| 黑人欧美特级aaaaaa片| 级片在线观看| 99久久99久久久精品蜜桃| 精品一区二区三区视频在线观看免费| 精品一区二区三区av网在线观看| 欧美日韩亚洲国产一区二区在线观看| 精品高清国产在线一区| 欧美不卡视频在线免费观看 | 大香蕉久久成人网| 人妻丰满熟妇av一区二区三区| 久热爱精品视频在线9| 久久国产乱子伦精品免费另类| 一个人免费在线观看的高清视频| 亚洲一卡2卡3卡4卡5卡精品中文| 日韩欧美国产在线观看| 老熟妇乱子伦视频在线观看| 国产91精品成人一区二区三区| tocl精华| 国产精品一区二区在线不卡| 好男人在线观看高清免费视频 | 69精品国产乱码久久久| 国产精品电影一区二区三区| 妹子高潮喷水视频| 人人妻人人爽人人添夜夜欢视频| 午夜精品在线福利| 高潮久久久久久久久久久不卡| 国产亚洲av高清不卡| 日韩欧美一区视频在线观看| 搡老妇女老女人老熟妇| 自拍欧美九色日韩亚洲蝌蚪91| 美女国产高潮福利片在线看| 久久狼人影院| 最近最新中文字幕大全免费视频| 国产亚洲欧美98| 欧美精品啪啪一区二区三区| 精品国产美女av久久久久小说| 如日韩欧美国产精品一区二区三区| netflix在线观看网站| 天堂动漫精品| 夜夜躁狠狠躁天天躁| 国产av一区二区精品久久| 两人在一起打扑克的视频| 一区二区三区高清视频在线| 一本久久中文字幕| 亚洲精品一卡2卡三卡4卡5卡| 欧美日韩亚洲综合一区二区三区_| 啦啦啦观看免费观看视频高清 | 看免费av毛片| 一二三四社区在线视频社区8| 黄色丝袜av网址大全| 国产真人三级小视频在线观看| 欧美色欧美亚洲另类二区 | 性欧美人与动物交配| 国产高清视频在线播放一区| 亚洲一卡2卡3卡4卡5卡精品中文| 免费在线观看影片大全网站| 欧美乱妇无乱码| 97人妻天天添夜夜摸| 亚洲精品中文字幕一二三四区| 国产成人精品久久二区二区免费| 欧美日本中文国产一区发布| 欧美一级a爱片免费观看看 | 他把我摸到了高潮在线观看| 国产片内射在线| 美女午夜性视频免费| 国产97色在线日韩免费| 国产精品久久久久久亚洲av鲁大| 精品熟女少妇八av免费久了| 精品电影一区二区在线| tocl精华| 一区二区三区高清视频在线| 免费在线观看黄色视频的| 国产一级毛片七仙女欲春2 | 国产成人免费无遮挡视频| 亚洲,欧美精品.| 日韩欧美在线二视频| 国产精品久久久av美女十八| 精品午夜福利视频在线观看一区| 亚洲成人精品中文字幕电影| 中出人妻视频一区二区| 国产精品久久久av美女十八| 老司机福利观看| 亚洲国产精品999在线| 日韩大码丰满熟妇| 99国产精品99久久久久| 午夜福利,免费看| svipshipincom国产片| 国产又色又爽无遮挡免费看| 精品无人区乱码1区二区| 不卡av一区二区三区| 久久精品人人爽人人爽视色| 亚洲欧美日韩高清在线视频| 精品国产一区二区三区四区第35| 久久久久久亚洲精品国产蜜桃av| 亚洲成人精品中文字幕电影| 欧美一级毛片孕妇| 亚洲欧美日韩无卡精品| 欧美中文日本在线观看视频| 欧美在线黄色| 午夜成年电影在线免费观看| 国产欧美日韩一区二区三| 一卡2卡三卡四卡精品乱码亚洲| 亚洲第一av免费看| 可以免费在线观看a视频的电影网站| 91成人精品电影| 国产麻豆成人av免费视频| 纯流量卡能插随身wifi吗| 国产色视频综合| 精品不卡国产一区二区三区| 午夜福利视频1000在线观看 | aaaaa片日本免费| 神马国产精品三级电影在线观看 | 欧美色视频一区免费| 亚洲精品国产区一区二| 国产色视频综合| 久久精品91蜜桃| 桃红色精品国产亚洲av| 动漫黄色视频在线观看| 午夜精品在线福利| 悠悠久久av| 别揉我奶头~嗯~啊~动态视频| 99久久久亚洲精品蜜臀av| 久9热在线精品视频| 亚洲精品中文字幕在线视频| 久久午夜亚洲精品久久| 亚洲中文字幕一区二区三区有码在线看 | 国产精品亚洲av一区麻豆| 久久欧美精品欧美久久欧美| 在线av久久热| 免费少妇av软件| 人妻久久中文字幕网| 国产又爽黄色视频| 欧美中文综合在线视频| 一进一出好大好爽视频| 九色国产91popny在线| 亚洲男人天堂网一区| 黑人欧美特级aaaaaa片| 亚洲精品美女久久av网站| 成人欧美大片| 极品教师在线免费播放| 美国免费a级毛片| 久久人妻熟女aⅴ| 少妇熟女aⅴ在线视频| 最近最新中文字幕大全免费视频| 黄色成人免费大全| 男人的好看免费观看在线视频 | 亚洲欧美日韩另类电影网站| or卡值多少钱| 国产色视频综合| 成年女人毛片免费观看观看9| 757午夜福利合集在线观看| 在线免费观看的www视频| 夜夜夜夜夜久久久久| 午夜两性在线视频| 国产精品自产拍在线观看55亚洲| 国产精品久久电影中文字幕| 大型黄色视频在线免费观看| 日韩大码丰满熟妇| 不卡av一区二区三区| 久久久国产精品麻豆| 国产精品一区二区免费欧美| 亚洲国产看品久久| 男人的好看免费观看在线视频 | 成人欧美大片| 极品教师在线免费播放| 欧美国产精品va在线观看不卡| 啪啪无遮挡十八禁网站| 激情视频va一区二区三区| 桃红色精品国产亚洲av| 女人被躁到高潮嗷嗷叫费观| 两人在一起打扑克的视频| 97人妻精品一区二区三区麻豆 | 久久久久久久久免费视频了| 国产精品久久久久久精品电影 | 国语自产精品视频在线第100页| av超薄肉色丝袜交足视频| 国产乱人伦免费视频| 十八禁人妻一区二区| 在线观看www视频免费| 一级作爱视频免费观看| 免费看a级黄色片| 精品午夜福利视频在线观看一区| 亚洲视频免费观看视频| 中文字幕久久专区| 国产精品av久久久久免费| 亚洲国产精品合色在线| 一区二区三区精品91| 少妇粗大呻吟视频| 如日韩欧美国产精品一区二区三区| ponron亚洲| 国产麻豆69| 午夜福利18| 亚洲男人的天堂狠狠| 亚洲第一青青草原| 久久久久久久久中文| 久久精品人人爽人人爽视色| 欧美国产精品va在线观看不卡| 色精品久久人妻99蜜桃| 久久久久久人人人人人| www国产在线视频色| 精品人妻在线不人妻| 精品久久久久久久久久免费视频| 亚洲人成77777在线视频| 少妇熟女aⅴ在线视频| 老鸭窝网址在线观看| 国产午夜福利久久久久久| 18禁黄网站禁片午夜丰满| 最好的美女福利视频网| 国产激情久久老熟女| 亚洲男人天堂网一区| 亚洲中文日韩欧美视频| 99国产精品一区二区蜜桃av| 妹子高潮喷水视频| 桃色一区二区三区在线观看| 国产免费av片在线观看野外av| 人人澡人人妻人| 一个人免费在线观看的高清视频| 激情在线观看视频在线高清| 后天国语完整版免费观看| 亚洲精品在线观看二区| 法律面前人人平等表现在哪些方面| 美女高潮喷水抽搐中文字幕| 咕卡用的链子| 久久久久久久久久久久大奶| 丝袜在线中文字幕| 国产区一区二久久| 少妇被粗大的猛进出69影院| 中文字幕最新亚洲高清| 国产精品,欧美在线| 国产在线精品亚洲第一网站| 一个人免费在线观看的高清视频| 午夜激情av网站| 国产熟女午夜一区二区三区| 久久久国产欧美日韩av| 最新美女视频免费是黄的| 欧美日韩中文字幕国产精品一区二区三区 | 亚洲av成人不卡在线观看播放网| 美女扒开内裤让男人捅视频| 天堂动漫精品| 欧美 亚洲 国产 日韩一| a在线观看视频网站| 黑人巨大精品欧美一区二区蜜桃| 午夜成年电影在线免费观看| 国产一区二区激情短视频| 少妇熟女aⅴ在线视频| 国产亚洲av嫩草精品影院| 一进一出抽搐gif免费好疼| 久久久久久亚洲精品国产蜜桃av| 国产91精品成人一区二区三区| 一区二区三区国产精品乱码| 一级片免费观看大全| 久久久久久人人人人人| 一卡2卡三卡四卡精品乱码亚洲| 中文字幕人妻丝袜一区二区| 老司机深夜福利视频在线观看| 久久精品成人免费网站| 99国产极品粉嫩在线观看| 久久伊人香网站| 国产亚洲欧美在线一区二区| 午夜激情av网站| 操出白浆在线播放| 日本 av在线| 免费观看精品视频网站| 欧美日韩乱码在线| 日韩中文字幕欧美一区二区| 久久久久久亚洲精品国产蜜桃av| 欧美激情 高清一区二区三区| 咕卡用的链子| 大香蕉久久成人网| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲在线自拍视频| 亚洲欧美一区二区三区黑人| 国产99白浆流出| 亚洲成国产人片在线观看| 午夜福利,免费看| 亚洲专区字幕在线| 久久久久九九精品影院| 午夜福利高清视频| 多毛熟女@视频| 亚洲av日韩精品久久久久久密| 日韩精品中文字幕看吧| 国产欧美日韩一区二区精品| 精品国产一区二区三区四区第35| 一级毛片精品| 国产精品 国内视频| 亚洲 国产 在线| svipshipincom国产片| 淫秽高清视频在线观看| 女同久久另类99精品国产91| 女人精品久久久久毛片| 黄片小视频在线播放| 国产精品亚洲美女久久久| 给我免费播放毛片高清在线观看| 国产在线观看jvid| 精品国内亚洲2022精品成人| 国产精品久久久久久人妻精品电影| 亚洲精品国产区一区二| 老司机福利观看| 国产午夜精品久久久久久| 欧美激情久久久久久爽电影 | 99re在线观看精品视频| 啦啦啦观看免费观看视频高清 | 身体一侧抽搐| 精品欧美一区二区三区在线| 黄色视频不卡| 一二三四在线观看免费中文在| 亚洲人成伊人成综合网2020| 国产精品久久久久久精品电影 | 国产精品久久久av美女十八| 亚洲 欧美一区二区三区| 满18在线观看网站| 少妇粗大呻吟视频| 日本在线视频免费播放| 国产av精品麻豆| 999久久久精品免费观看国产| 自拍欧美九色日韩亚洲蝌蚪91| 国产一区二区在线av高清观看| 9热在线视频观看99| 精品国产一区二区久久| av视频免费观看在线观看| 一级毛片高清免费大全| 国产精品 国内视频| 女人高潮潮喷娇喘18禁视频| 精品一区二区三区av网在线观看| 亚洲av熟女| 老熟妇仑乱视频hdxx| 午夜久久久在线观看| 嫩草影院精品99| 国产一级毛片七仙女欲春2 | av免费在线观看网站| 亚洲人成伊人成综合网2020| 亚洲av美国av| 一边摸一边抽搐一进一出视频| 精品国产一区二区久久| 亚洲av美国av| 老熟妇乱子伦视频在线观看| 很黄的视频免费| 男女床上黄色一级片免费看| 老熟妇乱子伦视频在线观看| aaaaa片日本免费| 天堂动漫精品| 国语自产精品视频在线第100页| 亚洲成a人片在线一区二区| 亚洲精品美女久久久久99蜜臀| av天堂在线播放| 午夜免费鲁丝| 老鸭窝网址在线观看| 欧美日本亚洲视频在线播放| 淫妇啪啪啪对白视频| 久久亚洲真实| 色在线成人网| 免费观看精品视频网站| 中国美女看黄片| 97人妻精品一区二区三区麻豆 | 国产乱人伦免费视频| 桃色一区二区三区在线观看| 欧美日本中文国产一区发布| 少妇 在线观看| 久久久久国产一级毛片高清牌| 19禁男女啪啪无遮挡网站| 亚洲人成网站在线播放欧美日韩| 色综合欧美亚洲国产小说| 亚洲狠狠婷婷综合久久图片|